AXGT · Sio Gene Therapies, Inc

-

Please sign in to comment on AXGT

1 Comment

Admin

4 years ago

Sio Gene Therapies, Inc is currently in a long term downtrend where the price is trading 15.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Sio Gene Therapies, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 25.1% to $-11M since the same quarter in the previous year.

Finally, its free cash flow grew by 9.4% to $-12M since the same quarter in the previous year.

Based on the above factors, Sio Gene Therapies, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	BMG0750W2037
Sector	Healthcare
Industry	Biotechnology

Market Cap	99M
PE Ratio	None
Target Price	8.5
Dividend Yield	0.0%
Beta	1.58

ABOUT

Sio Gene Therapies, Inc

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.

AXGT · Sio Gene Therapies, Inc

-

Sio Gene Therapies, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Sio Gene Therapies, Inc using a moving average strategy